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Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) transmission within endemic areas may vary. KSHV seroprevalence
has been studied by different groups of researchers using different methods, making it difficult to make direct
comparisons. Here we show results on KSHV seroprevalence using the same laboratory method from four different
but geographically proximate populations in Uganda.
Blood samples from the urban Entebbe Mother and Baby Study (EMaBS), the rural General Population Cohort (GPC),
the fishing community Lake Victoria Island Intervention Study on Worms and Allergy related Diseases (LaVIISWA)
and the high-risk sexual behaviour Good Health for Women Project (GHWP), were tested for IgG antibody levels to
K8.1 and ORF73 recombinant proteins using ELISA.
All adult participants of the EMaBS study and the GHWP were women, while the GPC (54% female) and LaVIISWA
(52% female) studies had both males and females. EMaBS children were all 5 years of age while their mothers were
14 to 47 years of age. GHWP women were 15 to 45 years old, LaVIISWA participants were 1 to 72 years old while
GPC participants were 1 to 103 years old. KSHV seropositivity varied in the different populations. In children aged 5
years, EMaBS had the lowest prevalence of 15% followed by GPC at 35% and LaVIISWA at 54%. In adult women,
seropositivity varied from 69% (EMaBS) to 80% (LaVIISWA) to 87% (GPC) to 90% (GHWP).
The reasons for the variation in prevalence are unclear but may reflect differences in the prevalence of cofactors
between these four geographically proximate populations.
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Key message
We show that KSHV prevalence varies even within geo-
graphically proximate locations in Uganda. This variations
could be caused by a number of co-factors including mal-
aria, HIV and helminths infections and early age of KSHV
infection. The high KSHV prevalence in various
populations may be explained by the multiple co-factors
that affect KSHV acquisition and transmission.
Introduction
Uganda has amongst the highest reported incidence of
Kaposi’s sarcoma (KS) in the world [1] and the highest
reported seroprevalence of the underlying causal agent,
Kaposi’s sarcoma-associated herpesvirus (KSHV) [2–4].
Unlike other human herpesviruses, KSHV varies in
prevalence widely across the world [5], perhaps reflect-
ing variation in underlying drivers of lytic replication
and transmission.
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Several risk factors for KSHV have been identified by
our group, and others, including infection with HIV,
malaria and helminths [2, 3, 6–11]. The distribution of
these may vary between regions within the same country
leading to differences in the spread of KSHV, even be-
tween geographically proximate locations.
In this manuscript, we have examined the seropreva-
lence of KSHV in four population cohorts in Uganda.
These cohorts include an urban population (Entebbe
Mother and Baby Study, EMaBS) [12], a land-locked
rural population (General Population Cohort, GPC) [13,
14], a rural fishing community population in the islands
of Lake Victoria (Lake Victoria Island Intervention Study
on Worms and Allergy related Diseases, LaVIISWA)
[15], and a high-risk sexual behaviour population re-
cruited in an urban centre, but including highly mobile
women who engage in transactional sex (Good Health
for Women Project, GHWP) [16].
Methods
Data on KSHV seropositivity from the EMaBS, the
GPC, LaVIISWA and the GHWP were analysed for
this manuscript. The study populations are described
briefly below and further details have previously been
published [12, 13, 15, 16].
The Entebbe Mother and Baby Study (EMaBS; ISRC
TN32849447) was a randomised double-blind, placebo-
controlled trial of anthelminthic treatment during preg-
nancy [12, 17–19], designed to investigate the effects of
helminth treatment during pregnancy on childhood re-
sponses to vaccines and infectious diseases. Pregnant
mothers in their second or third trimester attending
antenatal care at Entebbe general hospital were recruited
between June 2003 and August 2005. A total of 2507
pregnant women from the urban Entebbe municipality
and peri-urban Katabi sub-county (Fig. 1) were enrolled
in the EMaBS. Demographic and clinical details, blood
and stool samples were obtained from the mothers at
enrolment and 1 month after delivery, and from children
at ages one, two, three, four, five, 6 and 9 years. Using
plasma samples from mothers during early postpartum
period and 5 years old children, we tested for KSHV
antibody responses to determine KSHV seropositivity
and its associated risk factors [7, 9, 10, 20]. EMaBS pro-
vided a stable urban population relative to the other
populations analysed for this paper.
The General Population Cohort (GPC) is located in
southwestern Uganda, in Kyamulibwa sub-county of
Kalungu district [13, 21] (Fig. 1). The GPC has a popula-
tion of about 22,000 people scattered across the country-
side in 25 adjacent villages [22]. It is a rural community
with semi-permanent structures built from locally avail-
able materials. The community is relatively stable,
homogeneous and young, with 90% of residents aged
less than 50 years of age. Only about 13% of the resi-
dents attained education beyond primary level [23, 24].
The GPC was established to examine the trends and de-
terminants of the HIV epidemic in rural southwestern
Uganda [25, 26]. Biennial population surveys, as well as
medical surveys, are conducted at a central hub in each
village among all people who have lived in the village for
at least 3 months. During each medical survey, blood,
biophysical and lifestyle data are collected to determine
disease outcomes and risk factors for selected partici-
pants [27–29]. To determine KSHV seroprevalence in
this area, we have tested plasma samples for KSHV IgG
antibodies, collected at various survey rounds, the latest
tested being the 24th (2014/2015) and 25th (2016) sur-
veys [2].
The Lake Victoria Island Intervention Study on Worms
and Allergy-related diseases (LaVIISWA) was a two-arm
open cluster randomised trial (ISRCTN47196031) of
Fig. 1 Map showing the location of the study sites. EMaBS-Entebbe Mother and Baby Study, GPC-General Population Cohort, LaVIISWA-Lake
Victoria Island Intervention Study on Worms and Allergy related diseases, GHWP-Good Health for Women Project. Drawn from Google maps
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intensive versus standard antihelminthic treatment [30].
The trial was carried out in Lake Victoria island fishing
villages in Koome sub-county, Mukono district, Uganda
(Fig. 1), between September 2012 and August 2016. Kome
islands are relatively isolated and rural, consisting of
27 villages with a relatively mobile population of ap-
proximately 16,000 people; 26 of the villages partici-
pated in the trial with the remaining village used for
piloting procedures. The trial aimed to investigate the
effect of helminth treatment on allergy-related out-
comes in a Schistosoma mansoni heavily infected area.
Questionnaires were administered to record house-
hold features and socio-demographic characteristics
[31]. Plasma samples collected from the trial were
randomly selected and tested for KSHV IgG anti-
bodies to determine KSHV seropositivity [3].
The Good Health for Women Project (GHWP) is a
high-risk sexual behaviour cohort of women who engage
in transactional sex. Participants were recruited from a
densely populated slum area in southern Kampala, al-
though many were originally from rural areas and are
relatively mobile, some moving frequently to find work
(Fig. 1). These women work from bars, night clubs, local
beer breweries, eating places, lodges and guesthouses
known to provide rooms for commercial sex work. Re-
cruitment of over 1000 women into the GHWP oc-
curred in 2008 and three-monthly follow-up was carried
out. Details of the study are shown elsewhere [32, 33]. A
random sample of sera from 410 women in this cohort
was selected to determine KSHV seroprevalence.
All serological analyses were done in the same labora-
tory at the MRC/UVRI and LSTHM Uganda Research
Unit in Entebbe, Uganda. Plasma or serum samples were
tested for anti-KSHV IgG antibodies to KSHV-encoded
K8.1 and latently associated nuclear antigen (LANA)/
ORF73 recombinant proteins using an Enzyme-linked
immunosorbent assay (ELISA). Three negative control
wells and three positive control wells were included on
each plate. The negative controls were used to calculate
a cut-off value for each plate. The cut-off value for each
plate was the average background-subtracted optical
densities (OD) of the three negative control triplicates
plus a constant value of 0.75 (for K8.1) or 0.35 (for
ORF73/LANA). This procedure has been reported previ-
ously [34].
Statistical analysis was carried out using STATA ver-
sion 13 (StataCorp, College Station, Texas USA). The
survey study design of the LaVIISWA trial was not self-
weighting (because the number of households selected
from each village was fixed, therefore households from
smaller villages were more likely to be included in the
survey than households from larger villages). To allow
for this non-self-weighting design and to ensure that our
analyses are representative of the study area, we, there-
fore, took into account clustering within villages and ap-
plied village-level weights for all analyses [35, 36]. A
survey weight of one and a unique cluster number were
given to each participant from the other studies (EMaBS,
GPC and GHWP). Logistic regression (allowing for the
survey design) was used to determine associations be-
tween the study population and KSHV seropositivity.
Results
Plasma from 1164 EMaBS women and 1222 children
aged 5 years, 403 women aged 15 to 45 years from
GHWP, as well as males and females of all ages (7283
Table 1 Population characteristics
EMaBSa n = 2386 GPCb n = 7283 LaVIISWAc n = 1571 GHWPd n = 403
Sample collection years 2003/2006 2014/2016 2015/2016 2008/2009
Age in years, mean (range) 24 (14, 47)e 23 (1, 103) 23 (1, 72) 26 (15, 45)
Age groups, years
1–4 11% (833/7283) 14% (224/1571)
5 51% (1222/2386) 4% (315/7283) 4% (61/1571)
6–13 31% (2277/7283) 14% (228/1571)
14–18 8% (196/2386) 12% (848/7283) 6% (72/1571) 2% (9/402)
19–25 25% (594/2386) 8% (601/7283) 16% (255/1571) 46% (185/402)
26–50 16% (374/2386) 21% (1527/7283) 43% (672/1571) 52% (208/402)
Above 50 12% (882/7283) 4% (59/1571)
Sex, female 74% (1765/2386) 54% (3925/7283) 52% (770/1571) 100% (403/403)
HIV serostatus
Children (< 13 years) 2% (22/1221) 1% (36/3126) 2% (6/283)
Adults (14+ years) 14% (160/1164) 8% (315/3853) 21% (195/946) 38% (153/403)
HIV serostus determine using rapid diagnostic tests aEMaBS-Entebbe Mother and Baby Study, bGPC-General Population Cohort, cLaVIISWA-Lake Victoria Island
Intervention Study on Worms and Allergy related diseases, dGHWP-Good Health for Women Project, eOnly women from EMaBS, children were all 5 years old
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(GPC) and 1571 (LaVIISWA)) were analysed (Table 1).
HIV prevalence varied in the four different populations
with GHWP having the highest prevalence (38%), and
the GPC having the lowest (8%) among those aged 14
years and above (Table 1). Other population characteris-
tics of the participants analysed are shown in Table 1.
First, we looked at KSHV seropositivity in the various
age groups from the four different populations. KSHV
seropositivity increased with increasing age, (Fig. 2). The
urban Entebbe Mother and Baby Study had the lowest
seropositivity in all the tested age groups while the
GHWP had the highest seropositivity.
After considering the crude pattern of KSHV seropositiv-
ity, we then analysed the seropositivity of KSHV in the vari-
ous study populations adjusting for age, sex and HIV
serostatus. A separate statistical analysis of children aged 5
years was done because all EMaBS children included were
5 years old at the time of sampling. In these children, after
accounting for the effect of sex and HIV serostatus, the
odds of being KSHV seropositive were three times higher
in individuals from the GPC (OR= 3.08 (2.31, 4.12), p <
0.0001), and seven times higher in LaVIISWA (OR= 7.81
(3.67, 16.62), p < 0.0001), compared to individuals from
urban Entebbe (EMaBS); Table 2. This association was
maintained when the age of the child was accounted for
and all children aged 1 to 13 years were included in the
analysis (Table 2). The odds of being KSHV seropositive in
women 14 years and over was two times, three times and
four times higher in LaVIISWA (OR= 1.72 (1.22, 2.42), p =
0.002), GPC (OR= 2.61 (1.94, 3.52), p < 0.0001), and
GHWP (OR= 3.90 (2.72, 5.59), p < 0.0001) respectively,
compared to women from the EMaBS (Table 3). These dif-
ferences were maintained when only women of childbear-
ing age (14 to 49 years) were included in the analysis (Table
3). Furthermore, males over 14 years of age had similar
odds of being KSHV seropositive if they were from the
GPC and LaVIISWA (Table 3). GHWP and EMaBS had no
males over 14 years of age.
Discussion
The worldwide incidence of KS is known to vary greatly,
in large part reflecting variation in the prevalence of
KSHV, the underlying cause [5]. Less is known about
local variation between populations within countries,
perhaps because differences between published studies
may be attributed to differences between assays and ap-
proaches used, rather than reflecting real differences in
prevalence. In this paper, we take advantage of results
on KSHV seropositivity obtained from various Ugandan
populations, tested using the same antigens and carried
Fig. 2 KSHV seropositivity and 95% confidence intervals (CI). KSHV Seropositivity defined as reactivity to either ORF73 or K8.1 proteins. KSHV
antibodies were detected using ELISA. Seropositivity and 95% CI were obtained in STATA, allowing for the survey design. Graphs were drawn in
Graphpad Prism 8. EMaBS-Entebbe Mother and Baby Study, GPC-General Population Cohort, LaVIISWA-Lake Victoria Island Intervention Study on
Worms and Allergy related diseases, GHWP-Good Health for Women Project
Table 2 Association between KSHV seropositivity or antibody levels and study population. KSHV seropositivity in children
Study Children 1–13 years Children 5 years only
KSHV seropositivity *OR (95% CI), P value KSHV seropositivity **OR (95% CI), P value
EMaBSa 15% (184/1222) 1 15% (184/1222) 1
GPCb 47% (1597/3425) 3.16 (2.38, 4.19), < 0.0001 35% (111/315) 3.08 (2.31, 4.12), < 0.0001
LaVIISWAc 56% (305/513) 5.79 (3.82, 8.77), < 0.0001 54% (37/61) 7.81 (3.67, 16.62), < 0.0001
*Adjusted for age group, sex and HIV serostus ** Adjusted for sex and HIV serostatus. *OR: odds ratio. Logistic regression analysis was used for statistical analysis
allowing for the survey design for the LaVIISWA trial. aEMaBS-Entebbe Mother and Baby Study, bGPC-General Population Cohort, cLaVIISWA-Lake Victoria Island
Intervention Study on Worms and Allergy related diseases
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out by the same group of people from the same labora-
tory. Additionally, the glycoprotein K8.1 and the latent
protein latently associated nuclear antigen (LANA)/
ORF73 were used as antigens in the ELISA. These when
used in combination have been shown to be very specific
and sensitive at detecting HHV8 specific antibodies
[34, 37, 38]. In summary, we find that prevalence var-
ies significantly between cohorts recruited from geo-
graphically proximate locations.
Here we show that a relatively stable urban population
(EMaBS) has the lowest KSHV prevalence compared to
the other populations. This may be attributed to the
lower occurrence of putative risk factors for KSHV lytic
replication and transmission, such as, malaria and hel-
minthic parasites.
The GHWP population was included in the analysis
because of it’s uniqueness in comparison to the other
populations. It is an urban population with a high HIV
risk. It is a very mobile, high-risk sexual behaviour co-
hort with an HIV seroprevalence of 38%. These women
had the highest risk of being KSHV seropositive. This
KSHV risk is probably attributable to HIV and behav-
ioural practices, involving salivary exchange. Addition-
ally, many of the women are also highly mobile, moving
frequently between the urban setting and more rural
areas for work hence increasing their risk of acquiring
infections such as KSHV.
After GHWP, the Lake Victoria Island people and the
rural GPC people had higher KSHV seroprevalence
compared to EMaBS. The highly mobile Island commu-
nities of Lake Victoria have high HIV incidence, schisto-
somiasis, other infectious diseases [3]. We have
previously shown an association between schistosomiasis
infection and KSHV seropositivity and antibody levels in
these communities [3]. These factors may explain the
high risk of KSHV infection in this cohort. The rural
GPC is a relatively stable population but has a high
KSHV seropositivity probably due to factors such as fre-
quent malaria infections (many asymptomatic), which
could modulate the immune system impacting on KSHV
viral control and transmission.
In conclusion, KSHV prevalence varies even within
geographically proximate locations in Uganda. This vari-
ations could be caused by a number of co-factors includ-
ing malaria, HIV and helminths infections and early age
of KSHV infection. The high KSHV prevalence in vari-
ous populations may be explained by the multiple co-
factors that affect KSHV acquisition and transmission.
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